Loading...
₹ 0
0.00%
Loading...
About
Loading... [1]
- Market Cap ₹ 0 Cr.
- Current Price ₹ 0
- High / Low ₹ 0 / 0
- Stock P/E
- Dividend Yield 0 %
- ROE 0 %
- EPS 0
- P/B Ratio 0
- Net Profit Margin 0 %
- Debt to Equity 0
- ROCE 0 %
- Interest Coverage 0 %
Stock News - Aban
Latest updates related to Aban
Sr No. | Title | Sentiment |
---|---|---|
1 | The left needs to abandon its miserable, irrational pessimism | Aaron Bastani The Guardian | 🔄 |
2 | Lupin launches generic heart drug rivaroxaban in US CNBCTV18 | 🔄 |
3 | Lupin launches Rivaroxaban drug in US Business Standard | 🔄 |
4 | Lupin shares rise nearly 3% on launch of Rivaroxaban Tablets USP, in the US The Economic Times | 🔄 |
5 | Lupin unveils heart drug Rivaroxaban in US Medical Dialogues | 🔄 |
6 | Lupin launches Rivaroxaban Tablets USP, 2.5 mg in the US Business Standard | 🔄 |
7 | Pharma stock jumps 3% after company to launch Rivaroxaban Tablets in U.S. Trade Brains | 🔄 |
8 | Arrested MahaBank ex-manager in six-day police custody Onmanorama | 🔄 |
9 | Individual investors own 12% of Bank of Maharashtra (NSE:MAHABANK) shares but state or government control 80% of the company Simply Wall St | 🔄 |
10 | Bank Of Maharashtra Q3 Results 2025 - Find Bank Of Maharashtra Q3 Earnings Result | MAHABANK Q3 results Mint | 🔄 |
Loading peers table...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Loading data...
Quarterly Data Visualization
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Loading Profit & Loss data...
Profit & Loss Data Visualization:
Compounded Sales Growth | |
---|---|
10 Years: | |
5 Years: | |
3 Years: | |
TTM: |
Compounded Profit Growth | |
---|---|
10 Years: | |
5 Years: | |
3 Years: | |
TTM: |
Stock Price CAGR | |
---|---|
10 Years: | |
5 Years: | |
3 Years: | |
1 Year: |
Return on Equity | |
---|---|
10 Years: | |
5 Years: | |
3 Years: | |
Last Year: |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Balance Sheet Data Visualization:
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Ratios
Consolidated Figures in Rs. Crores / View Standalone